Conjoined triplets

29 Oct 2013 By Robert Cyran

A two-year diet has done more for investors than a decade of acquisitions. The drug giant still trades at a 10 pct discount to rivals – fodder for CEO Ian Read to push for a breakup. And Pfizer’s recovery should encourage others to find similar solutions to sluggish performance.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)